0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Plasma Anti–Amyloid-β Autoantibodies in All Alzheimer Disease Types

Lucio Tremolizzo, MD, PhD; Elisa Conti, PhD; Ildebrando Appollonio, MD; Carlo Ferrarese, MD, PhD
Arch Neurol. 2012;69(11):1525-1527. doi:10.1001/2013.jamaneurol.6.
Text Size: A A A
Published online

Extract

We read with great interest the recent work published in the Archives by Dorothée and colleagues1 assessing plasma levels of naturally occurring anti–amyloid-β (Aβ) IgG in Alzheimer disease (AD) and patients with posterior cortical atrophy with evidence of AD (PCA-AD). The authors elegantly pointed out a difference in the pattern of acid-dissociated total anti-Aβ IgG plasma levels, especially types 1 and 3, in PCA-AD with respect to subjects with typical AD. Interestingly, these antibodies have been proposed to play a protective role2; therefore, differences in their expression profile might imply relevant pathologic and phenotypic variability in AD. We recently reported that free plasma levels of anti-Aβ IgG in patients with AD are reduced and that therapy with acetylcholinesterase inhibitors (AChEIs) selectively increases them up to the levels expressed by healthy control subjects,3 possibly owing to an effect of phenotypic modification on T lymphocytes.4 As already emphasized,1 methodologic differences might explain the disagreement among different series. However, increased anti-Aβ IgG plasma levels in patients with AD with respect to PCA-AD might be also related to differences in AChEI treatment. In fact, the percentage of patients with PCA-AD treated with these drugs might be lower with respect to subjects with typical AD, given that AChEIs are regarded as symptomatic drugs, mainly, albeit not only, working on damaged cholinergic pathways involved in episodic memory, typically relatively preserved in patients with PCA-AD in the initial phases of the disease.5 If true, then the difference in anti-Aβ IgG levels reported by Dorothée and colleagues might simply reflect the different frequency of AChEI treatment between their 2 pathologic groups.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

November 1, 2012
Guillaume Dorothée, PhD; Leonardo Cruz de Souza, MD, PhD; Marie Sarazin, MD, PhD; Pierre Aucouturier, PhD
Arch Neurol. 2012;69(11):1525-1527. doi:10.1001/archneurol.2012.2779.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();